Traditional Chinese Medicine Molecule RA-V: A Potential Synergistic Factor in KRAS G12C Inhibition
The KRAS G12C mutation is one of the common driver mutations in malignant tumors such as colorectal cancer (CRC) and non-small cell lung cancer (NSCLC). Recently approved KRAS G12C inhibitors like Adagrasib (MRTX849) and Sotorasib have provided unprecedented therapeutic options for patients.
危险品化学品经营许可证（带存储）